Paul Baas, MD, PhD, of the Netherlands Cancer Institute, discusses results of the CheckMate 743 trial, which suggests nivolumab plus ipilimumab should be considered the new standard of care in first-line treatment of unresectable malignant pleural mesothelioma, regardless of the histology subtype (Abstract 3).
Misako Nagasaka, MD, of the Barbara Ann Karmanos Cancer Institute, discusses results of the ORIENT-11 trial, which showed that, although sintilimab ...
Marina C. Garassino, MD, of the Istituto Nazionale dei Tumori di Milano, discusses the global registry she and her colleagues created to track and a...
Leora Horn, MD, of Vanderbilt University, discusses phase III results from the eXalt3 trial, which suggest that ensartinib, a novel, next-generation...